About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: HALO
- CUSIP: 40637H10
- Previous Close: $12.51
- 50 Day Moving Average: $12.06
- 200 Day Moving Average: $11.17
- 52-Week Range: $7.18 - $14.38
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.41
- P/E Growth: -0.26
- Market Cap: $1.55B
- Outstanding Shares: 128,154,000
- Beta: 2.27
- Net Margins: -44.60%
- Return on Equity: -405.28%
- Return on Assets: -26.67%
Companies Related to Halozyme Therapeutics:
- Debt-to-Equity Ratio: -16.66%
- Current Ratio: 5.18%
- Quick Ratio: 4.93%
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?
8 brokerages have issued 1 year price targets for Halozyme Therapeutics' shares. Their predictions range from $6.75 to $20.00. On average, they expect Halozyme Therapeutics' stock price to reach $14.25 in the next year.
When will Halozyme Therapeutics announce their earnings?
Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Halozyme Therapeutics stock?
Halozyme Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Third Security LLC (15.06%), Iridian Asset Management LLC CT (8.38%), FMR LLC (5.28%), State Street Corp (2.98%), Franklin Resources Inc. (0.81%) and MSD Partners L.P. (0.75%). Company insiders that own Halozyme Therapeutics stock include Kenneth J Kelley and Laurie Stelzer.
Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?
Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Allianz Asset Management AG, Brown Advisory Inc., Renaissance Technologies LLC, Guggenheim Capital LLC, J. Goldman & Co LP and Metropolitan Life Insurance Co. NY.
Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?
Halozyme Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Iridian Asset Management LLC CT, State Street Corp, Oxford Asset Management, A.R.T. Advisors LLC, Russell Investments Group Ltd., Pacad Investment Ltd. and Trexquant Investment LP.
How do I buy Halozyme Therapeutics stock?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Halozyme Therapeutics stock cost?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $12.07.